{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:22:15Z","timestamp":1786119735549,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/mjt.0b013e31820543c5","type":"journal-article","created":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T03:17:01Z","timestamp":1297394221000},"page":"e157-e166","source":"Crossref","is-referenced-by-count":47,"title":["Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy"],"prefix":"10.1097","volume":"19","author":[{"given":"Eric Q.","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Forsythe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Latremouille-Viau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Tsaneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-10-20210202","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0149-2918(03)80158-3","article-title":". A literature review of the epidemiology and treatment of acute gout.","volume":"25","author":"Kim","year":"2003","journal-title":"Clin Ther"},{"key":"R3-10-20210202","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":". Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R4-10-20210202","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","article-title":". Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.","volume":"67","author":"Annemans","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 5","key":"R5-10-20210202","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3949\/ccjm.75.Suppl_5.S9","article-title":"Epidemiology of gout.","volume":"75","author":"Weaver","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"R6-10-20210202","first-page":"240","article-title":"Gout: can management be improved Curr Opin Rheumatol.","volume":"13","author":"Schlesinger","year":"2001","journal-title":""},{"key":"R7-10-20210202","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.080487","article-title":". Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter.","volume":"36","author":"Wu","year":"2009","journal-title":"J Rheumatol"},{"key":"R8-10-20210202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R9-10-20210202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":". Serum urate levels and gout flares: analysis from managed care data.","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"R10-10-20210202","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout.","volume":"334","author":"Emmerson","year":"1996","journal-title":"N Engl J Med"},{"key":"R11-10-20210202","first-page":"198","article-title":"Refractory gout: what is it and what to do about it Curr Opin Rheumatol.","volume":"20","author":"Fels","year":"2008","journal-title":""},{"key":"R12-10-20210202","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1002\/art.23803","article-title":"Treatment-failure gout: a moving target.","volume":"58","author":"Edwards","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R13-10-20210202","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review.","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"R14-10-20210202","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.1780290111","article-title":"The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality.","volume":"29","author":"Singer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"R15-10-20210202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0889-857X(21)00376-8","article-title":"Treatment of refractory crystal-associated arthritis.","volume":"21","author":"Rosenthal","year":"1995","journal-title":"Rheum Dis Clin North Am"},{"key":"R16-10-20210202","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":". Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"R17-10-20210202","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":". Febuxostat compared with allopurinol in patients with hyperuricemia and gout.","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R18-10-20210202","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":". Efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"R19-10-20210202","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","article-title":". The effect of serum urate on gout flares and their associated costs: an administrative claims analysis.","volume":"15","author":"Halpern","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"R20-10-20210202","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18553\/jmcp.2008.14.2.164","article-title":". Disease-related and all-cause healthcare costs of elderly patients with gout.","volume":"14","author":"Wu","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"R21-10-20210202","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1185\/030079906X112606","article-title":". The economic burden of gout on an employed population.","volume":"22","author":"Brook","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R22-10-20210202","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":". A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R23-10-20210202","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R24-10-20210202","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2007.081604","article-title":"Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans.","volume":"67","author":"Singh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R25-10-20210202","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":". Quality of life and disability in patients with treatment-failure gout.","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"R26-10-20210202","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.1780160402","article-title":"The past four decades of progress in the knowledge of gout, with an assessment of the present status.","volume":"16","author":"Gutman","year":"1973","journal-title":"Arthritis Rheum"},{"issue":"Suppl l","key":"R27-10-20210202","first-page":"S459","article-title":"Clinical, humanistic, and economic outcomes of gout.","volume":"15","author":"Brixner","year":"2005","journal-title":"Am J Manag Care"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MJT.0b013e31820543c5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:53:19Z","timestamp":1786042399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201211000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31820543c5","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}